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Objective: To describe the utility of high frequency jet ventilation (HFJV) as a rescue 
therapy in patients with respiratory failure secondary to respiratory syncytial virus (RSV) 
that was refractory to conventional mechanical ventilation (CMV).
Design: Descriptive study by retrospective review.
setting: Pediatric intensive care unit at a tertiary care children’s hospital.
Patients: Infants on mechanical ventilation for respiratory failure due to RSV.
interventions: Use of HFJV.
Main results: Eleven patients were placed on HFJV. There was sustained improvement 
in ventilation on HFJV with a mean decrease in PCO2 of 9 mmHg at 24 h and 11 mmHg 
at 72 h. There were no significant changes in oxygenation by oxygenation index. No 
patients required extracorporeal support or suffered pneumothorax, pneumomediasti-
num, or subcutaneous emphysema. Ten out of 11 (91%) patients survived to discharge 
from the hospital.
conclusion: High frequency jet ventilation may represent an alternative therapy for RSV-
induced respiratory failure that is refractory to CMV.
Keywords: respiratory insufficiency, respiratory acidosis, respiratory syncytial virus, high frequency ventilation, 
high frequency jet ventilation, bronchiolitis
inTrODUcTiOn
Respiratory syncytial virus (RSV) is one of the most common causes of lower respiratory tract infec-
tion in children worldwide, causing a substantial disease burden. In a large population-based study 
in the USA, RSV bronchiolitis was responsible for 22–24% of outpatient visits and an estimated 
75,000–125,000 annual hospital admissions in the USA (1). Of hospitalized children with RSV-
related illness, approximately 10–20% require critical care due to acute respiratory insufficiency 
and require admission to the pediatric intensive care unit (PICU) with intubation and mechanical 
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ventilation (2). About 5% of intubated patients require more sup-
port than conventional ventilation can provide.
Ventilation index (VI), which takes into account PaCO2 
in relation to respiratory support, has been correlated with 
an increased risk of death in children with acute respiratory 
failure, and it has been proposed that alternative modalities 
be sought when VI is greater than 65 (3). In these patients, 
the use of rescue therapies such as high frequency oscilla-
tory ventilation (HFOV) and extracorporeal membranous 
oxygenation (ECMO) has been advocated (4–6). Patient 
characteristics associated with more severe disease and 
adverse outcomes include prematurity, young age, chromo-
somal abnormalities, cardiac disease, and neuromuscular 
disease (1, 5, 6).
Infants with respiratory failure from RSV can present 
with diverse clinical presentations characterized by distinct 
pathophysiology. Some patients primarily exhibit increased 
lower airway resistance with airway edema, mucus plugging, 
and dynamic hyperinflation. Other patients primarily exhibit 
a disease of decreased static compliance similar to acute 
respiratory distress syndrome (ARDS), with alveolar disease, 
decreased functional residual capacity, and intrapulmonary 
shunting (7, 8). Infants who develop ARDS from RSV are 
more likely to be younger and have premorbid conditions 
such as prematurity, congenital heart disease, and immu-
nodeficiency compared to those who have more obstructive 
disease (7).
High frequency jet ventilation (HFJV) has been described in 
patients with air leak/bronchopleural fistula (9), in infants with 
pulmonary interstitial emphysema (10), and ARDS (11, 12). 
We report our single institution experience with HFJV in RSV 
respiratory failure with severe derangements in oxygenation and 
ventilation not responding to conventional mechanical ventila-
tion (CMV).
MaTerials anD MeThODs
A list of intubated children with RSV who were treated with 
HFJV from October 2010 through May 2012 was obtained from 
the Virtual PICU database (Virtual PICU Systems, LLC). In these 
patients with clinical bronchiolitis, RSV was confirmed by rapid 
antigen test or PCR from respiratory tract secretions.
Medical records were retrospectively examined for the follow-
ing data: age of patient, premorbid conditions, sex, weight, days 
of illness, indication for intubation, peak conventional ventilator 
settings, arterial or capillary blood gases before and after the 
initiation of HFJV, and HFJV settings. Total time spent on each 
mode of mechanical ventilation was calculated and any addi-
tional or rescue therapies to improve ventilation, such as airway 
lavage with or without bronchoscopy and the use of heliox were 
documented. Full conventional mechanical ventilator support 
was defined as tidal volume of 7–9 mL/kg with minimum set rate 
of 26 breaths per minute. The VI was calculated as [respiratory 
rate × (PIP-PEEP) × PCO2]/1000.
This study was approved by the Institutional Review Board at 
Wayne State University School of Medicine and Detroit Medical 
Center.
inclusion/exclusion criteria
Patients were included if they had RSV bronchiolitis and 
transitioned to HFJV from CMV. Reasons for the patients to 
be transitioned from CMV to HFJV were categorized as: (a) 
hypercapnic respiratory failure if patients had a PIP greater 
than 35 cmH2O for more than 6 h associated with persistent 
respiratory acidosis (pH ≤  7.25, PCO2 >  60  mmHg) or (b) 
hypoxemic respiratory failure with ARDS as defined by Berlin 
criteria (13).
Ventilation strategy
All intubated RSV patients were managed with pressure-con-
trolled, synchronized intermittent mandatory ventilation (SIMV) 
as the initial ventilation mode. Puritan Bennett 840 (Covidien, 
Mansfield, MA, USA), Hamilton G-5 (Reno, NV, USA) and 
E vent–Inspiration 5i (San Clemente, CA, USA) were used for 
mechanical ventilation.
High frequency jet ventilation was delivered by Life Pulse 
HFJV (Bunnell Inc., Salt Lake City, UT, USA) in tandem with 
a conventional ventilator. HFJV settings were chosen with an 
initial FiO2 of 1.0, and a rate of 360–420 per minute with an 
inspiratory time of 0.02 sec. Peak inflation pressure was initiated 
at 40 cmH2O and titrated based on PCO2 clearance. The PEEP 
of the conventional ventilator functions as the source for the 
mean airway pressure (MAP) of the system and was titrated to 
achieve a MAP 2–3 cmH2O higher than the MAP on conven-
tional ventilation prior to initiating HFJV. A beginning rate of five 
conventional ventilator breaths per minute was titrated down to 
zero as MAP was optimized (see http://www.bunl.com/technical.
html for diagram of HFJV setup).
statistical analysis
For descriptive statistics, categorical variables are presented 
using absolute counts and percentage. Continuous variables are 
presented using medians and range. Bivariate correlations were 
performed with continuous data and Spearman’s correlation with 
ordinal data. Comparisons conducted between variables were 
done with related-samples Wilcoxon Signed Rank test. Adverse 
event data are reported using raw numbers, percentages, and 
ratios. SPSS version 21.0 was utilized for analyses; p < 0.05 was 
considered to be significant.
resUlTs
During the time frame of evaluation, there were 75 patients admit-
ted with RSV-related respiratory failure. Eleven patients met the 
inclusion criteria for the study; all had community acquired RSV. 
One patient received 2 courses of HFJV, thus constituting a total 
of 12 courses. Baseline characteristics and brief clinical summa-
ries of the patients are presented in Table 1. Nine out of the 11 
patients were prematurely born, and 3 were on oxygen at baseline. 
One patient had trisomy 21 with an unrepaired ventricular septal 
defect. Only one subject was a previously healthy, full-term infant. 
Two patients initially met criteria for mild ARDS while the other 
nine met criteria for moderate to severe ARDS based on the 2012 
Berlin definition (13).
TaBle 1 | Patient characteristics and clinical course summary.
Pt age  
(wks)
Wt  
(kg)
comorbid Via Oia hFJV  
days
MV  
days
icU  
days
Other clinical events
1 26 2.4 24-week premature female, 
home oxygen
132 32 7 19 27 Bronchoscopies (4), surfactant, no complications, survived
2 2 1.7 35-week premature male, 
chronic lung disease
54 20 7 24 33 iNO, bronchoscopies (2), no complications, survived
3 3 4.7 Previously healthy female 71 7 4 7 8 No complications, survived
4 156 14.2 26-week premature male b 12 7 9 14 PCO2 at the time of HFJV initiation 92 mmHg. No 
complications, survived
5.1 13 4.2 34-week premature male, 
home oxygen for first 
6 weeks of life
52 11 1 23 32 1st HFJV course: HFJV 1 day discontinued for hypercarbia, 
received heliox and surfactant. 2nd HFJV course: HFJV 
5 days, bronchoscopies (3). Subglottic stenosis, survived
5.2 85 8 5 23 32
6 8 4.8 36-week premature male 52 11 1 5 6 No complications, survived
7 4 3.0 34-week premature male 62 12 6 13 16 No complications, survived
8 8 4.4 34-week premature female, 
liver abscess
b 37 9 24 30 PCO2 at HFJV initiation 71 mmHg. Inotropes, 
bronchoscopies (2), no complications, survived
9 4 2.9 Trisomy 21, VSD, 35-week 
premature female
33 14 10 17 37 Bronchoscopy once, no complications, survived
10 3 4 31-week premature female, 
on home oxygen
40 17 6 11 13 Bronchoscopies (2), no complications, survived
11 26 4.7 24-week premature female, 
on MV first 4 months of life, 
on home oxygen
b 28 2 10 12 Pre-HFJV on HFOV for ARDS, pneumothorax, surfactant. 
HFJV 2 days with worsening ARDS. On inotropes, multiple 
organ failure, died
aVI and OI calculated at time of HFJV initiation where data available.
bConventional mechanical ventilation data not available to calculate VI at baseline for patients 4, 8, and 11.
TaBle 2 | Therapies (n = 12 hFJV courses); data are absolute counts (%).
Inhaled nitric oxide 2 (17)
Heliox 1 (8)
Mucolytic therapy 3 (25)
Surfactant 3 (25)
Palivizumab (SynagisR) 0 (0)
Systemic corticosteroids 0 (0)
ECMO 0 (0)
Antibiotics 6 (50)
Bronchoalveolar lavage 7 (58)
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For all 12 courses, HFJV was used as a rescue therapy for 
ventilatory failure with hypoxia and/or hypercapnia refractory to 
CMV. The pre-HFJV VI was available for nine patients. The mean 
and median VI were 65 and 54, respectively (range of 33–132). 
All subjects had hypercapnic respiratory failure defined as an 
elevated PCO2 with respiratory acidosis despite full conventional 
mechanical support. Other therapies used in the clinical care 
of these patients are presented in Table  2. Of note, no patient 
received preventative RSV immune globulin despite the eligibility 
of all but one patient.
The mean PCO2 before HFJV initiation was 72 mmHg (range 
57–102  mmHg), and decreased from baseline by 9  mmHg at 
24 h, 12 mmHg at 48 h (p = 0.018), and 11 mmHg at 72 h after 
starting HFJV. Figure  1 shows individual patients as well as 
the mean PCO2 over time. The mean and median oxygenation 
index (OI) before starting HFJV were 17 and 14, respectively 
(range 5–32). The mean and median OI at 72 h were both 12 
(range 2–24). There was no significant change in OI over this 
time frame.
None of the patients received ECMO. There were no complica-
tions of pneumothorax, pneumomediastinum, or subcutaneous 
emphysema associated with HFJV in this cohort. One patient 
developed subglottic stenosis. One patient died.
DiscUssiOn
In patients with severe respiratory failure refractory to CMV, 
rescue therapies have been described, such as HFOV and ECMO 
(14–17). However, ECMO carries considerable morbidity and 
mortality. According to a query of the Extracorporeal Life 
Support (ELSO) registry from 1993 to 2007, the mortality of 
children who required ECMO for RSV pneumonia was 30%, and 
the mortality of children with chronic lung disease who required 
ECMO for respiratory failure was 41% (18). In addition to the 
risk of morbidity and mortality, an ECMO program requires 
substantial resources, expertise, and surgical support. Although 
a case report and small case series (16, 19, 20) describe the use 
of HFOV in obstructive airway disease, the use of HFOV in 
patients with severe obstruction to airflow has the potential to 
worsen air trapping and hyperinflation and may be considered a 
contraindication for use (21).
The pathophysiology of pediatric respiratory failure from RSV 
can be represented by a polarized clinical spectrum. One end of 
the spectrum is airway obstruction caused by bronchiolitis, which 
is characterized by airway edema, bronchial and bronchiolar 
FigUre 1 | PcO2 change for each individual and the combined mean after hFJV initiation. The combined means are represented as the dotted line.
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obstruction, and mucus plugging. This can lead to wheezing, pro-
longed and incomplete exhalation with air trapping and auto- or 
intrinsic PEEP as well as radiographic evidence of hyperinflation. 
The other end of the spectrum of respiratory failure from RSV is 
pneumonitis characterized by pathophysiology similar to ARDS. 
This is manifested by edema and inflammation of the alveoli and 
pulmonary interstitium resulting in reduced compliance (7). 
The resulting atelectasis and multifocal airspace disease lead to 
intrapulmonary shunting, ventilation-perfusion mismatch, and 
hypoxemia. Although the clinical manifestations of RSV lower 
respiratory tract disease in any given patient can overlap, many 
patients exhibit a predominance of either obstructive or restric-
tive lung disease causing respiratory failure.
Maintenance of adequate FRC in patients with pneumonia/
ARDS manifestations and avoidance of auto-PEEP and air-
trapping in those with obstructive airways are major challenges. 
In some children, CMV fails to improve oxygenation/ventilation, 
and rescue therapies such as high frequency ventilation and 
ECMO are sought. If the outcomes were similar, HFV would be 
preferable to ECMO because of the less invasive nature and less 
technical support needed for implementation and management.
In such patients, HFJV offers certain theoretical advantages 
compared to HFOV. The equal pressure point (EPP) where 
intrathoracic pressure during exhalation is equal to intraluminal 
pressure, is shifted distally (toward the alveoli) in diseases char-
acterized by airway obstruction such as RSV bronchiolitis (22). 
The active expiration of HFOV creates negative pressure in the 
proximal airway that may not be uniformly dissipated distally 
because of prolonged time constant due to increased resistance. 
This leads to excessive transmural pressure resulting in proximal 
airway collapse, further increase in airway resistance, and air 
trapping. Transmural pressure favoring proximal airway collapse 
also occurs with the use of HFJV, but its magnitude is expected 
to be much less compared to that of HFOV because exhalation is 
passive and intraluminal pressure remains positive throughout 
exhalation (Figure 2).
High frequency jet ventilation offers some advantages in pul-
monary hygiene over HFOV. Suctioning the airway may be done 
by way of an inline suction catheter with HFJV while the system 
is often opened for suctioning on HFOV, potentially resulting in 
alveolar derecruitment. Additionally, the physics of gas exchange 
peculiar to HFJV are beneficial in removing airway debris and in 
management of hyperinflation, both of which cause physiologic 
derangement in respiratory failure from RSV. HFJV delivers 
short pulses of high velocity inspired gas described as “transi-
tional flow,” which preferentially travels much faster through 
the center of the airways where the drag is less. In RSV, these 
pulses of inspired air move past secretions coating the airways. 
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The slower-moving exhaled gas spirals around the outer aspects 
of the airway, contributing to augmented removal of airway 
debris. This is consistent with previous reports describing the 
use of HFJV to augment the mobilization of obstructing casts 
in plastic bronchitis (23), and to remove debris in meconium 
aspiration (24).
The cohort of subjects in the present study represents the more 
severe spectrum of respiratory failure from RSV. Of 75 mechani-
cally ventilated patients with acute respiratory failure from RSV 
infection, 11 were ill enough to be considered for rescue therapy. 
Nine of these 11 patients had pre-existing chronic lung disease of 
prematurity, which carries higher risk of mortality. Five patients 
had bronchopulmonary dysplasia, four of them being on sup-
plemental oxygen at home. Three patients had a VI ≥  70; one 
patient had an OI ≥  32 prior to the initiation of HFJV. These 
patients represent the extremes of acute hypercapnic and hypoxic 
respiratory failure for whom extracorporeal support would be a 
reasonable option. They were successfully supported with HFJV 
until such time as they were able to be weaned off mechanical 
respiratory support. One patient developed subglottic stenosis, 
the other nine recovered to their pre-illness baseline for respira-
tory support. One patient in our study died, and that patient was 
deemed a poor candidate for ECMO due to pre-existing severe, 
chronic lung disease and prolonged cardiopulmonary arrest prior 
to arrival to the hospital.
Limitations of this study include the retrospective nature, 
small sample size, and lack of uniformity in HFJV management. 
However, the significance of these exploratory findings is the 
relative success of HFJV as an alternative treatment for severe 
ventilatory failure from RSV.
cOnclUsiOn
This case series describes the utility of HFJV as an alternative, res-
cue therapy for RSV-induced respiratory failure that is refractory 
to CMV. HFJV was tolerated by this group of patients without 
FigUre 2 | schematic comparison with theoretical pressures reflecting dynamic changes in airway caliber during hFOV and hFJV. The active 
exhalation of HFOV with negative intraluminal pressure is expected to result in greater increase in transmural pressure compared with passive exhalation of HFJV 
where intraluminal pressure remains positive throughout exhalation. This would lead to greater collapse of the proximal airway and higher expiratory resistance and 
air trapping especially in an obstructive disease (such as RSV bronchiolitis) in HFOV compared with HFJV. Transmural pressure equals intrapleural pressure minus 
airway (alveolar) pressure. See text for further explanation.
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evidence of new/worsened chronic lung disease. The utility of 
HFJV should be further explored in this patient population as an 
alternative therapy for severe, refractory ventilatory failure.
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